MedPath

A comparative study of safety and efficacy of bilastine updosing (40mg) vs combination of bilastine 20mg with levocetrizine 5mg in the treatment of chronic spontaneous urticaria

Not Applicable
Conditions
Health Condition 1: L49-L54- Urticaria and erythema
Registration Number
CTRI/2022/10/046449
Lead Sponsor
SRM Medical college hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

patients previously treated with bilastine 20mg for 2 weeks but developing new lesions

Exclusion Criteria

Hereditary angioedema

Food or drug allergy

Collagen vascular diseases

Atopic dermatitis

Systemic autoimmune disorders

Hodgkinââ?¬•s disease

Pregnant and lactating women

Patients on systemic or topical corticosteroids within 4 weeks

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath